前立腺癌において癌抑制型マイクロRNA-223はインテグリンシグナル（ITGA3/ITGB1）を制御して癌細胞の遊走能・浸潤能を抑制する by KUROZUMI, Akira & 黒住, 顕
Tumor-suppressive microRNA-223 inhibits cancer cell migration and 
invasion by targeting ITGA3/ITGB1 signaling in prostate cancer 
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Summary 
Analysis of microRNA (miRNA) expression signatures in prostate cancer 
(PCa) and castration-resistant PCa (CRPC) has revealed that 
microRNA-223 (miRNA-223) is significantly downregulated in cancer 
tissues, suggesting that miR-223 acts as a tumor-suppressive miRNA 
by targeting oncogenes. The aim of this study was to investigate the 
functional roles of miR-223 and identify downstream oncogenic targets 
regulated by miR-223 in PCa cells. Functional studies of miR-223 were 
performed to investigate cell proliferation, migration, and invasion 
using PC3 and PC3M PCa cell lines. Restoration of miR-223
significantly inhibited cancer cell migration and invasion in PCa 
cells. In silico database and genome-wide gene expression analyses 
revealed that ITGA3 and ITGB1 were direct targets of miR-223
regulation. Knockdown of ITGA3 and ITGB1 significantly inhibited 
cancer cell migration and invasion in PCa cells by regulating 
downstream signaling. Moreover, overexpression of ITGA3 and ITGB1 
was observed in PCa clinical specimens. Thus, our present data 
indicated that downregulation of miR-223 enhanced ITGA3/ITGB1
signaling and contributed to cancer cell migration and invasion in 
PCa cells. Elucidation of the molecular pathways modulated by 
tumor-suppressive miRNAs provides insights into the mechanisms of 
PCa progression and metastasis. 
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INTRODUCTION 
Prostate cancer is the most common cause of cancer in men, 
accounting for about one-quarter of all cancer cases in men.(1)
Multiple treatment options are available for localized PCa, and the 
5-year survival rate is nearly 100%; however, effective curative 
treatments for advanced PCa have not been developed.(2) Skeletal 
metastasis is one of the most common and important features of 
advanced PCa.(3) Metastatic PCa is initially treated with 
androgen-deprivation therapy (ADT); however, the cancer gradually 
becomes resistant to first-line ADT and progresses to 
castration-resistant PCa (CRPC).(2) Progression of PCa to metastatic 
disease significantly affects the survival of men with PCa. Therefore, 
developing a deeper understanding of the molecular mechanisms of 
metastatic pathways underlying PCa metastasis using novel approaches 
will facilitate the development of novel treatment options for 
advanced PCa. 
Normal regulatory mechanisms can be disrupted by the aberrant 
expression of tumor-suppressive or oncogenic microRNAs (miRNAs) in 
cancer cells. Therefore, identification of aberrantly expressed 
miRNAs is an important first step toward elucidating the details of 
miRNA-mediated oncogenic pathways. Based on this background, we have 
identified tumor-suppressive miRNAs and the molecular targets and 
pathways regulated by these miRNAs on the miRNA expression signatures 
of PCa and CRPC specimens.(4-11) Recent studies of several miRNA 
signatures in PCa showed that miR-223 expression is frequently 
reduced in cancer tissues compared to with that in normal prostate 
tissues,(4, 12, 13) suggesting that miR-223 acts as a tumor suppressor 
in PCa. 
Integrins are cell surface receptors for extracellular matrix 
proteins, and integrin-mediated signaling plays a key role in cell 
survival, proliferation, migration, and invasion in normal and 
malignant cells.(14, 15) Studies have shown that silencing of these 
genes significantly inhibits cell migration and invasion in cancer 
cells through targeting its downstream signaling.  
The aim of the present study was to investigate the functional 
significance of miR-223 and to identify the molecular targets and 
downstream signaling pathways regulated by miR-223 in PCa cells. Our 
data demonstrated that restoration of mature miR-223 inhibited cancer 
cell? migration and invasion. Moreover, gene expression data and in 
silico database analysis showed that the genes coding for integrin 
A3 (ITGA3) and integrin B1 (ITGB1)were potential targets of miR-223
regulation. The discovery that tumor-suppressive miR-223 regulated 
integrin genes provides important insights into the potential 
mechanisms of PCa metastasis and suggests novel therapeutic 
strategies for the treatment of PCa. 
MATERIALS AND METHODS
Clinical prostate specimens and cell culture
Seventeen patients with PCa who had undergone radical 
prostatectomy at Chiba University Hospital (Chiba, Japan) from 2009 
to 2013 and twenty-nine patients with elevated PSA who had undergone 
transrectal needle biopsy at Teikyo University Chiba Medical Center 
(Ichihara, Japan) from 2008 to 2013 were enrolled in this study. The 
patients’ backgrounds are summarized in Table 1. As for prostatectomy 
specimens, seventeen paired samples of PCa and corresponding normal 
tissues were obtained. As for needle biopsy specimens, a pair of 
needle biopsy specimens was collected from the same region as from 
patients in this study, and one was subjected to pathological 
verification. The normal tissues were free of cancer cells, as 
determined by pathological examination. Before tissue collection, 
written informed consent of tissue donation for research purposes 
was obtained from patients. The protocol was approved by the 
Institutional Review Board of Chiba University and Teikyo University. 
For in vitro analyses, we used human PCa cell lines (PC3 and PC3M) 
obtained from the American Type Culture Collection (Manassas, VA, 
USA). These cells were maintained in RPMI-1640 medium supplemented 
with 10% fetal bovine serum in a humidified atmosphere of 5% CO2 and 
95% air at 37°C. 
RNA extraction 
Total RNA was extracted from formalin-fixed paraffin-embedded 
(FFPE) samples with four 5-µm thick slices, using miRNeasy FFPE Kit 
(Qiagen, Hilden, Germany) according to the manufacturer’s protocol.  
Quantitative real-time reverse transcription polymerase chain 
reaction (qRT-PCR) 
The procedure for PCR quantification was described previously.(11, 
16, 17) TaqMan probes and primers for ITGA3 (P/N: Hs01076873_ml; Applied 
Biosystems, Foster City, CA, USA), ITGB1 (P/N: Hs00559595_ml; Applied 
Biosystems), and ACTB (the internal control; P/N: Hs01060665_gl; 
Applied Biosystems) were assay-on-demand gene expression products. 
The expression levels of miR-223 (Assay ID: 002295; Applied 
Biosystems) were analyzed by TaqMan quantitative real-time RT-PCR 
(TaqMan MicroRNA Assay; Applied Biosystems) and normalized to the 
expression of RNU48 (Assay ID: 001006; Applied Biosystems). All 
reactions were performed in triplicate, and each assay included 
negative control reactions that lacked cDNA.  
Mature miRNA, siRNA and plasmid vector transfection
The following miRNA and siRNAs were used: Pre-miR miRNA precursor 
(hsa-miR-223-3p; P/N: AM12301; Applied Biosystems), Stealth Select 
RNAi siRNAs; si-ITGA3 (cat nos. HSS105529 and HSS179967; Invitrogen), 
si-ITGB1 (cat nos. HSS105559 and HSS105561; Invitrogen), and negative 
control miRNA/siRNA (P/N: AM17111; Applied Biosystems). RNAs were 
incubated with OPTI-MEM (Invitrogen) and Lipofectamine RNAiMax 
transfection reagent (Invitrogen) as described previously.(11, 16, 17)
     For ITGA3 or ITGB1 rescue experiments, 2.5µg of pF4A CMV 
Flexi-plasmid vector containing ITGA3 or ITGB1 (C848A; Promega, 
Madison, WI, USA) were transfected 24 h before miRNAs transfection 
by using Lipofectamin 2000 transfection reagent (Life Technologies,  
Carlsbad, CA, USA). 
Cell proliferation, migration, and invasion assays 
Cell proliferation, migration, and invasion assays were 
performed as previously described.(11, 16, 17)
Western blotting  
Cells were harvested 72 h after transfection, and lysates were 
prepared. Next, 20 µg of each cell lysate was separated on 
Mini-PROTEAN TGX Gels (Bio-Rad, Hercules, CA, USA) and transferred 
to PVDF membranes. Immunoblotting was performed with rabbit 
anti-ITGA3 antibodies (1:250 dilution; HPA008572; Sigma-Aldrich, St. 
Louis, MO, USA), rabbit anti-ITGB1 antibodies (1:1000 dilution; 9699; 
Cell Signaling Technology, Danvers, MA, USA), rabbit anti-FAK 
antibodies (1:1000 dilution; #3285; Cell Signaling Technology), 
anti-phospho-FAK (Tyr397) (D20B1) rabbit monoclonal antibodies 
(mAbs) (1:1000 dilution; #8556; Cell Signaling Technology), anti-Akt 
(pan) (11E7) rabbit mAbs (1:1000 dilution; #4685; Cell Signaling 
Technology), anti-phospho-Akt (Ser473) (D9E) XP rabbit mAbs (1:1000 
dilution; #4060; Cell Signaling Technology), anti-Src (32G6) rabbit 
mAbs (1:1000 dilution; #2123; Cell Signaling Technology), 
anti-phospho-Src family (Tyr416) (D49G4) rabbit mAbs (1:1000 
dilution; #6943; Cell Signaling Technology), anti-p44/42 
mitogen-activated protein kinase (MAPK; also known as extracellular 
signal-regulated kinase [ERK] 1/2) antibodies (1:1000 dilution; 
#9102; Cell Signaling Technology), anti-phospho-p44/42 MAPK 
(Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP rabbit mAbs (1:1000 
dilution; #4370; Cell Signaling Technology), and anti-GAPDH 
antibodies (1:1000 dilution; ab8245; Abcam, Cambridge, UK) as a 
loading control. The membranes were washed and incubated with 
anti-rabbit IgG horseradish peroxidase (HRP)-linked antibodies 
(#7074; Cell Signaling Technology). Complexes were visualized with 
Clarity Western ECL Substrate (Bio-Rad). 
Screening of miR-223 target genes using in silico analysis and 
genome-wide gene expression analysis 
To identify miR-223 target genes, we used in silico analysis and 
genome-wide gene expression analysis, as described previously.(18, 
19) The strategy for selection of miR-223 target genes is shown in 
Supplemental Fig. 1. 
Plasmid construction and dual-luciferase reporter assay 
Partial wild-type sequences of the ITGA3/ITGB1 3’-untranslated 
region (UTR) or those with deleted miR-223 target sites were inserted 
between the XhoI–PmeI restriction sites in the 3’-UTR of the hRluc 
gene in the psiCHECK-2 vector (C8021; Promega, Madison, WI, USA). 
The synthesized DNA was cloned into the psiCHECK-2 vector. PC3 cells 
were transfected with 50 ng of the vector and 10 nM miR-223 using 
Lipofectamine 2000 (Invitrogen). The activities of firefly and 
Renilla luciferases in cell lysates were determined with a 
dual-luciferase assay system (E1910; Promega). Normalized data were 
calculated as the ratio of Renilla/firefly luciferase activities. 
Immunohistochemistry 
A total of 17 radical prostatectomy specimens were used (Table 
1). Tissue specimens were immunostained using an Ultra-Vision 
Detection System (Thermo Scientific, Fremont, CA, USA) according to 
the manufacturer’s instructions. Primary rabbit polyclonal 
antibodies against ITGA3 (HPA008572; Sigma-Aldrich) were diluted 
1:15, and primary mouse monoclonal antibodies against ITGB1 (ab3167; 
Abcam) were diluted 1:100. The slides were treated with biotinylated 
goat antibodies. 
A tissue microarray containing 60 PCa specimens, 10 prostatic 
intraepithelial neoplasias (PINs), and 10 prostatic hyperplastic 
samples was obtained from Provitro (Berlin, Germany) (Cat #401 2209, 
Lot #146.1 P020212,26-46, Berlin, BRD). Detailed information on all 
cancer specimens can be found at 
http://www.provitro.com/fileadmin/provitro-data/TMA/4012209.pdf. 
Immunostaining was evaluated according to the scoring method as 
described previously.11
Statistical analysis 
The relationships between two groups and the numerical values 
obtained by real-time RT-PCR were analyzed using the Mann–
Whitney U-test. The relationships among three variables and 
numerical values were analyzed using the Bonferroni-adjusted Mann–
Whitney U-test. All analyses were performed using Expert StatView 
(version 5; SAS Institute Inc., Cary, NC, USA). 
RESULTS 
Expression levels of miR-223 in PCa clinical specimens and cell lines 
To validate our past PCa miRNA signature results, we evaluated 
the expression levels of miR-223 in 34 radical prostatectomy 
specimens and 29 transrectal needle biopsy specimens. The expression 
levels of miR-223 were significantly lower in PCa clinical specimens 
than in noncancerous specimens (P = 0.0069; Fig. 1A, P = 0.0184; Fig. 
1B). miR-223 expression was also reduced in PC3 and PC3M cells 
compared with that in noncancerous specimens. 
Although it was not able to assess the correlation between miR-223
expression and clinicopathological characteristics due to limited 
number of clinical specimens. The cohort study with increased number 
of specimens will be important in the future. 
Effects of miR-223 restoration on cell proliferation, migration, and 
invasion in PCa cells 
To investigate the functional effects of miR-223, we performed 
gain-of-function studies using miRNA transfection of PC3 and PC3M 
cells.
XTT assays revealed significant inhibition of cell proliferation 
in PC3 and PC3M cells transfected with miR-223 in comparison with 
mock- or control-transfected cells (PC3: P < 0.0001; PC3M: P = 0.0002; 
Fig. 1C). 
Similarly, wound healing assays demonstrated significant 
inhibition of cell migration activities in miR-223 transfectants 
compared with that in mock- or miR-control-transfected cells (PC3: 
P = 0.0176; PC3M: P < 0.0001; Fig. 1D). 
Moreover, Matrigel invasion assays revealed that miR-223
transfection significantly inhibited cell invasion. The number of 
invaded cells was significantly reduced in miR-223-transfected cells 
(PC3: P < 0.0001; PC3M: P < 0.0001; Fig. 1E). 
Identification of candidate target genes of miR-223 in PCa cells 
To identify target genes of miR-223, we performed a combination 
of in silico and oligomicroarray analyses. First, we performed 
genome-wide gene expression analysis using PC3 and PC3M cells. A total 
of 936 genes that were downregulated (average log2 ratio < -0.5) 
following miR-223 transfection as compared with expression levels 
in miR-control-transfected cells were selected. Next, we screened 
these genes using the TargetScan database and found that 247 genes 
had putative target sites for miR-223 in their 3’-UTRs. Finally, we 
categorized these genes into KEGG pathways using GENECODIS analysis; 
14 pathways were identified as significantly enriched pathways (Table 
2). 
Because miR-223 significantly inhibited cancer cell migration 
and invasion, we focused on three annotations: extracellular matrix 
(ECM)-receptor interaction, regulation of actin cytoskeleton, and 
focal adhesion. These three annotations all included ITGA3 and ITGB1; 
therefore, these genes were subjected to further analysis. 
Immunohistochemical detection of ITGA3 and ITGB1 in PCa clinical 
specimens 
Next, we examined the expression levels of ITGA3 and ITGB1 in 
PCa specimens by immunohistochemical staining. ITGA3 and ITGB1 were 
strongly expressed in several cancer tissues, while low expression 
was observed in normal tissues (Fig. 2 and Supplemental Fig. 3). To 
gain further insights whether upregulation of ITGA3 and ITGB1 
correlate with clinicopathological features, we used tissue 
microarray (Supplementary table 1). Immunostaining was evaluated 
according to the scoring method as described previously.(11) Each case 
was scored on the basis of the intensity and area of staining. Both 
upregulation of ITGA3 and ITGB1 were confirmed in the PCa tissue 
compared with non-PCa tissue (Supplementary Fig. 4, P = 0.0294 and 
P = 0.0003). The expression levels of ITGA3 or ITGB1 were not 
associated with clinicopathological features of PCa in this analysis. 
ITGA3 and ITGB1 were directly regulated by miR-223 
We then performed qRT–PCR and western blotting to confirm that 
restoration of miR-223 resulted in downregulation of ITGA3 and ITGB1 
in PC3 and PC3M cells. The mRNA and protein expression levels of ITGA3 
and ITGB1 were significantly repressed in miR-223 transfectants in 
comparison with mock or miR-control transfectants (PC3: P = 0.0051; 
PC3M: P = 0.0029; Figs. 3A and 3B, PC3: P = 0.0014; PC3M: P = 
0.0017; Figs. 4A and 4B).  
We performed luciferase reporter assays in PC3 cells to determine 
whether ITGA3 and ITGB1 mRNAs were directly regulated by miR-223. 
The TargetScan database predicted that putative miR-223-binding 
sites existed in the 3?-UTR of ITGA3 (position 635–641; Fig. 3C) 
and of ITGB1 (position 255–261; Fig. 4C). We used vectors encoding 
either the partial wild-type sequence of the 3?-UTR of ITGA3 or 
ITGB1 mRNA, including the predicted miR-223 target sites, or 
deletion vectors lacking the miR-223 target sites. We found that the 
luminescence intensities were significantly reduced by transfection 
with miR-223 and vectors carrying the wild-type 3?-UTR of ITGA3 and 
ITGB1, whereas transfection with deletion vectors blocked the 
decrease in luminescence (P < 0.0001 and p < 0.0001, respectively; 
Figs. 3D and 4D). These data suggested that miR-223 bound directly 
to specific sites in the 3’-UTRs of ITGA3 and ITGB1 mRNA. 
Effects of silencing ITGA3 and ITGB1 on cell proliferation, migration, 
and invasion in PCa cells 
To investigate the functional role of ITGA3 and ITGB1 in PCa cells, 
we performed loss-of-function studies using si-ITGA3 and si-ITGB1
transfectants. First, we evaluated the knockdown efficiency of 
si-ITGA3 and si-ITGB1 transfection in PC3 cells. qRT-PCR and western 
blotting indicated that si-ITGA3 transfection effectively 
downregulated ITGA3 expression and that si-ITGB1 transfection 
effectively downregulated ITGB1 expression in PC3 cells (P < 0.0005, 
and P < 0.0001, respectively; Figs. 5A and 5B). 
In functional assays, cell proliferation, cell migration, and 
invasion assays demonstrated that cancer cell proliferation, 
migration, and invasion activity were significantly inhibited in 
si-ITGA3-transfected PC3 cells in comparison with mock- or 
si-control-transfected PC3 cells (P < 0.0001, P < 0.0001, and P < 
0.0001, respectively; Figs. 5C–5E). Similarly, transfection with 
si-ITGB1 significantly inhibited cancer cell proliferation, 
migration, and invasion (P < 0.0001, P < 0.0001, and P < 0.0001, 
respectively; Figs. 5F–5H). 
We also evaluated the knockdown efficiency of si-ITGA3 and 
si-ITGB1 transfection in PC3M cells (Supplemental Fig. 2). Cancer 
cell proliferation, migration, and invasion activity were 
significantly inhibited in si-ITGA3- and si-ITGB1-transfected cells 
in comparison with mock- or si-control-transfected cells 
(Supplemental Fig. 2). 
Effects of co-transfection of ITGA3/miR-223 or ITGB1/miR-223 in PC3 
cell line 
To confirm the miR-223-ITGA3 or miR-223/ITGB1 mediating 
anti-tumour effect in PCa cells, we co-expressed ITGA3 or ITGB1 and 
miR-223 in PCa cells. ITGA3 or ITGB1 rescue studies indicated that 
cell migration and invasion properties were rescued by ITGA3 or ITGB1
transfectants as compared with cells restored miR-223 only 
(Supplemental Figs. 3A and 3B). These data suggested that role of 
ITGA3 or ITGB1 protein were modulated by miR-223 and effects of 
migration and invasion in PCa cells. 
Effects of ITGB1 knockdown on ITGB1 downstream signaling  
We analyzed the effects of ITGA3/ITGB1 knockdown on downstream 
signaling in PC3 cells using si-ITGA3 and si-ITGB1 transfectants. 
To examine the effects of knockdown on ITGB1-mediated survival 
pathways, the phosphorylation of FAK (Tyr 397), SRC (Tyr 416), AKT 
(Ser 473) and ERK1/2 (Thr 202/Tyr 204) was examined. Knockdown of 
ITGB1 greatly reduced the phosphorylation of FAK, SRC, AKT, and ERK1/2 
(Fig. 6). In contrast to knockdown of ITGB1, knockdown of ITGA3 did 
not cause changes in the phosphorylation levels of these proteins 
(data not shown). 
Discussion
A growing body of evidence has indicated that normal RNA 
regulatory mechanisms can be disrupted by the aberrant expression 
of tumor-suppressive or oncogenic miRNAs in cancer cells. Therefore, 
identification of aberrantly expressed miRNAs is an important first 
step toward elucidating novel miRNA regulatory networks in PCa cells. 
Based on this, we constructed the miRNA expression signatures of PCa 
and CRPC using clinical specimens and identified tumor-suppressive 
miRNAs regulating novel oncogenic pathways.(5-12) CRPC is difficult 
to treat using currently available therapies, and most clinical 
trials for advanced PCa have shown limited benefits, with disease 
progression and metastasis to the bone or other sites.(3) Thus, 
understanding the molecular mechanisms of the metastatic signaling 
pathways underlying PCa using current genomic approaches would help 
to improve therapies for and prevention of the disease. Our miRNA 
signatures in PCa revealed that miR-223 was significantly 
downregulated in naïve PCa and CRPC tissues. In the present study, 
we validated the downregulation of miR-223 in PCa clinical specimens. 
Additionally, we focused on miR-223 and investigated the functional 
roles of miR-223 and miR-223-regulated novel oncogenic pathways in 
PCa.  
In this study, we evaluated the low expression of miR-223 and 
the effects of miR-223 regulation on metastatic signaling pathways 
in PC3 and PC3M cells, two representative PCa cell lines. PC3M cells 
were derived from a liver metastasis in a nude mouse bearing a spleen 
explant of PC3 cells; these cells have increased metastatic ability 
compared with PC3 cells.(20, 21) Restoration of miR-223 significantly 
inhibited cancer cell migration and invasion in both PC3 and PC3M 
cells, suggesting that miR-223 acts as a tumor-suppressive miRNA in 
PCa cells. The tumor-suppressive function of miR-223 has been 
reported in various other types of cancers and is thought to occur 
through regulation of several oncogenic genes.(22, 23) Previous reports 
have shown that insulin-like growth factor-1 (IGF-1R) is directly 
regulated by miR-223 and that restoration of miR-223 inhibits cell 
proliferation through suppression of downstream phosphoinositol 
3-kinase/AKT/mammalian target of rapamycin pathways.(24, 25) Moreover, 
overexpression of miR-223 suppresses cell proliferation in 
colorectal cancer, cervical cancer, and hepatoma cells by targeting 
forkhead box transcriptional factor 1 (FOXO1).(26) These findings 
indicate that miR-223 is downregulated in cancer cells and functions 
as a tumor-suppressive miRNA by targeting oncogenic genes.  
In contrast to our data, a recent report showed that expression 
of miR-223 is upregulated in PCa tissues and cell lines, including 
LNCaP, DU145, and PC3 cells.(27) Moreover, knockdown of miR-223 using 
antisense oligonucleotides leads to G0/G1 arrest and induces 
apoptosis in LNCaP, DU145, and PC3 cells.(27) Another study showed 
that overexpression of miR-223 in primary gastric carcinoma is 
associated with poor metastasis-free survival.(28) Interestingly, 
overexpression of miR-223 has been shown to result in acquisition 
of invasive ability in nonmetastatic gastric cancer cells.(28) Thus, 
these studies of miR-223 indicate that this miRNA has opposing roles 
as s tumor suppressor or oncogene in different types of cancer cells. 
Therefore, it is necessary to investigate the molecular targets and 
RNA networks regulated by miR-223 in different types of cancers. Our 
recent data of CRPC miRNA expression signature showed that miR-223
was significantly reduced in CRPC specimens.(12) Downregulation of 
miR-223 in PCa specimens has reported by other group based on deep 
sequencing analysis.(29) These data strongly suggest that miR-223 was 
frequently reduced in PCa tissues and acts as a tumor suppressor. 
Recent bioinformatic predictions have indicated that miRNAs 
regulate more than 30–60% of protein-coding genes in the human 
genome.(30, 31) Improving our understanding of miR-223-mediated targets 
and signaling pathways in PCa may provide important insights into 
the mechanisms of PCa metastasis. We used a combination of genome-wide 
gene expression analysis and in silico analysis to identify novel 
molecular targets and pathways regulated by tumor-suppressive miRNAs 
in cancer cells.(4-11) Using this strategy, we identified several 
pathways and targets regulated by miR-223 in PCa cells. Among them, 
we further investigated the ITGA3 and ITGB1 genes, which are involved 
in focal adhesion and ECM receptor interaction according to KEGG 
pathway analysis. Integrins are a large family of cell surface 
receptors composed of specific two subunits (α and β) that bind to 
ECM components. Most types of cells require integrin-mediated 
signaling pathways for proliferation, migration, invasion, and 
survival.(14, 15) ITGA3 and ITGB1 are components of a specific subset 
of integrins and are expressed PCa cells.(14, 15, 31-33)
In this study, we confirmed the upregulation of ITGA3 and ITGB1 
in PCa clinical specimens. We showed that ITGA3 and ITGB1 were 
directly regulated by miR-223 and that silencing of ITGA3 or ITGB1
significantly inhibited cancer cell migration and invasion in PC3 
and PC3M cells. Moreover, our present data showed that knockdown of 
ITGB1 inhibited downstream signals contributing to cell adhesion and 
invasion. Overexpression of ITGB1 has been observed in several cancer 
types in previous studies.(32, 33) Additionally, a recent study showed 
that ITGB1 is activated in highly metastatic PCa cells, but not in 
prostate cancer cells with low metastatic potential or normal 
prostate epithelial cells.(34) ECM ligands and Talin-1 have been shown 
to induce the activation of ITGB1 in cancer cells.(34, 35) Interestingly, 
our recent studies showed that tumor-suppressive miR-29s and miR-218
are frequently downregulated in cancer cells, including PCa cells, 
and cause upregulation of ECM components.(9, 17, 36) Moreover, expression 
of Talin-1 is increased in metastatic tissues compared with that in 
primary prostate tumors.(37) Thus, these studies indicate that 
aberrant expression of miRNAs disrupts tightly regulated 
integrin-mediated signaling in the prostate and promotes cancer cell 
migration and invasion.  
In conclusion, downregulation of miR-223 was validated in PCa 
clinical specimens, and these miRNAs were shown to function as tumor 
suppressors in PCa. To the best of our knowledge, this is the first 
report demonstrating that tumor-suppressive miR-223 directly 
targeted ITGA3 and ITGB1 in PCa cells. Moreover, these integrins were 
upregulated in PCa clinical specimens and contributed to cancer cell 
migration and invasion. Metastatic progression of PCa significantly 
impacts the survival of men with prostate cancer. Suppression of 
ITGA3/ITGB1 signaling in PCa cells may have applications in the 
development of novel therapies for PCa. 
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Figure legends 
Fig. 1. Expression levels of miR-223 in PCa clinical specimens and 
PCa cell lines (PC3 and PC3M). (A-B) Quantitative real-time RT-PCR 
showed that the expression levels of miR-223 were significantly lower 
in PCa tissues and PCa cell lines than in normal prostate tissues. 
RNU48 was used as an internal control. Effects of miR-223 transfection 
on PCa cell lines (PC3 and PC3M). (C) Cell proliferation was 
determined by XTT assays at 72 h after transfection with miR-223 (10 
nM). (D) Cell migration activity was determined by wound-healing 
assays at 48 h after transfection with miR-223 (10 nM). (E) Cell 
invasion activity was determined by Matrigel invasion assays at 48 
h after transfection with miR-223 (10 nM). *P < 0.05.  
Fig. 2. Immunohistochemical staining of ITGA3 and ITGB1 in clinical 
specimens of prostate cancer and normal prostate tissues. (A) ITGA3 
was expressed more strongly in several cancer lesions than in normal 
tissues. (B) ITGB1 was also overexpressed in cancer lesions. 
Fig. 3. The expression of ITGA3 was suppressed by transfection of 
PCa cell lines (PC3 and PC3M) with miR-223. (A) ITGA3 mRNA expression 
was evaluated by qRT-PCR at 72 h after transfection with miR-223 (10 
nM). ACTB was used as an internal control. *P < 0.01. (B) ITGA3 protein 
expression was evaluated by western blotting at 72 h after 
transfection with miR-223 (10 nM). GAPDH was used as a loading control. 
(C) miR-223 binding site in the 3’-UTR of ITGA3 mRNA. (D) Luciferase 
reporter assays in PC3 cells using vectors encoding a putative miR-223
target site at position 635–641 of ITGA3 3’-UTR. Renilla luciferase 
values were normalized to firefly luciferase values. *P < 0.0001.  
Fig. 4. ITGB1 expression was suppressed by transfection of PCa cell 
lines (PC3 and PC3M) with miR-223. (A) ITGB1 mRNA expression was 
evaluated by qRT-PCR at 72 h after transfection with miR-223 (10 nM). 
ACTB was used as an internal control. *P < 0.005. (B) ITGB1 protein 
expression was evaluated by western blotting at 72 h after 
transfection with miR-223 (10 nM). GAPDH was used as a loading control. 
(C) miR-223 binding site in the 3’-UTR of ITGB1 mRNA. (D) Luciferase 
reporter assays in PC3 cells using vectors encoding a putative miR-223
target site at position 255-261 of the ITGB1 3’-UTR. Renilla
luciferase values were normalized to firefly luciferase values. *P
< 0.0001.
Fig. 5. Expression levels of ITGA3 and ITGB1 were suppressed by 
transfection of PC3 cells with si-ITGA3 and si-ITGB1. (A-B) ITGA3
and ITGB1 mRNA expression levels were evaluated by qRT-PCR at 72 h 
after transfection with si-ITGA3 and si-ITGB1 (10 nM). ACTB was used 
as an internal control. *P < 0.0005. ITGA3 and ITGB1 expression levels 
were evaluated by western blotting at 72 h after transfection with 
si-ITGA3 and si-ITGB1 (10 nM). GAPDH was used as a loading control. 
(C–E) Effects of ITGA3 silencing on PC3 cells. (C) Cell proliferation 
was determined by XTT assays. (D) Cell migration activity was 
determined by wound-healing assays. (E) Cell invasion activity was 
determined by Matrigel invasion assays. (F–H) Effects of silencing 
ITGB1 on PC3 cells. (F) Cell proliferation was determined by XTT 
assays. (G) Cell migration activity was determined by wound-healing 
assays. (H) Cell invasion activity was determined by Matrigel 
invasion assays. *P < 0.0001.   

Fig. 6. Effects of ITGB1 knockdown on ITGB1 downstream signaling. 
Knockdown of ITGB1 in PC3 cells reduced the phosphorylation of FAK 
(Tyr 397), SRC (Tyr 416), AKT (Ser 473), and ERK1/2 (Thr 202/Tyr 204). 
Supplemental Fig. 1. Effects of ITGA3 and ITGB1 silencing on PC3M 
cells. 
Supplemental Fig. 2. Strategy for selecting target pathways regulated 
by miR-223 in PCa cells. 
Supplemental Fig. 3. 
Effects of co-transfection of ITGA3/miR-223 or ITGB1/miR-223 in PC3 
cell line. 
(A-B) Cell migration and invasion assays on PC3 cells  transfected 
with miR-223 only, with miR-223/ITGA3 or miR-223/ITGB1. *P < 0.0001. 
(C-D) ITGA3 or ITGB1 protein expression levels were measured by 
Western Blot after 48 h ITGA3 or ITGB1-expression vector transfection 
on PC3 cells. GAPDH was used for a loading control.
Supplemental Fig. 4. 
Immunohistochemical staining of ITGA3 or ITGB1 in PCa by tissue 
microarray. 
(A) Quantification of ITGA3 expression, PCa (n=51), PIN (n=10), and 
normal prostatic tissue (n=10) by tissue microarray. Strongly 
stained cancer lesions (pT4N0, Gs 3+4, pT2bN0, Gs 3+4). (B) 
Quantification of ITGB1 expression. Strongly stained cancer 
lesions (pT3aN0, GS 3+4, pT2bN0, Gs 3+4).
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